Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Financial Summary
Consolidated Financial Results for the Six Months ended September 30, 2026 (FY2026)
(Japanese standard)

October 29, 2026

Listed company name: JCR Pharmaceuticals Co., Ltd.
Listed stock exchange: Tokyo Stock Exchange
Code number: 4552 URL: https://jcrpharm.com/
Representative: (Title) Representative Director, President
(Name) Hiroyuki Sonoda
Person in charge of inquiries: (Title) Managing Executive Officer, Executive Director, Corporate Strategy Division
(Name) Yoh Ito TEL: 0797(32)1995

Scheduled date to file Semiannual Securities Report: November 13, 2026
Scheduled date to commence dividend payments: December 4, 2026
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated Financial Results for the Six Months Ended September 30, 2026 (from April 1, 2026 to September 30, 2026)

(1) Consolidated Operating Results (cumulative) (Percentages indicate year-on-year changes.)

	Net sales		Operating profit(loss)		Ordinary profit(loss)		Profit (loss) attributable to owners of parent	
Six months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
September 30, 2026	19,974	(6.5)	(3,504)	—	(3,798)	—	(3,867)	—
September 30, 2025	21,362	28.2	2,429	–	2,413	–	1,746	–

(Note) Comprehensive income: For the six months ended September 30, 2026: (4,859) million yen (-%)
For the six months ended September 30, 2025: 2,263 million yen (26.5%)

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
September 30, 2026	(31.67)	—
September 30, 2025	14.32	14.31

(Note) "Diluted earnings per share" for six months ended September 30, 2026 is not stated because there was a net loss per share, even though there were residual shares.

(2) Consolidated Financial Conditions

	Total assets	Net assets	Equity ratio
As of	Million yen	Million yen	%
September 30, 2026	113,876	41,389	35.9
March 31, 2026	109,236	47,359	42.9

(Reference) Shareholders' equity: As of September 30, 2026: 40,921 million yen
As of March 31, 2026: 46,868 million yen

2. Cash Dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	—	10.00	—	10.00	20.00
Fiscal year ended March 31, 2027	—	10.00			
Fiscal year ended March 31, 2027 (Forecast)			—	10.00	20.00

(Notes) Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated Forecasts for the Fiscal Year Ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentage figures for the fiscal year represent the changes from the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Fiscal year ended March 31, 2027	45,700	13.3	1,100	98.2	500	(57.1)	200	(90.8)	1.64

(Notes) Revisions to the forecast of financial results most recently announced: None

*Notes

(1) Significant Changes in the Scope of Consolidation during the Period: None

(2) Adoption of Accounting Treatment Specific to the Preparation of Semiannual Consolidated Financial Statements: None

(3) Changes in Accounting Policies, Changes in Accounting Estimates, and Restatement

1. Changes in accounting policy due to the revision of accounting standards, etc. : None
2. Changes in accounting principles other than 1. : None
3. Changes in accounting estimates : None
4. Restatements : None

(4) Number of Issued Shares (common shares)

1. Total number of issued shares at the end of the period (including treasury shares)	As of September 30, 2026	129,686,308 shares	As of March 31, 2026	129,686,308 shares
2. Number of treasury shares at the end of the period	As of September 30, 2026	7,434,678 shares	As of March 31, 2026	7,693,402 shares
3. Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)	Six months ended September 30, 2026	122,117,184 shares	Six months ended September 30, 2025	121,901,549 shares

* Review of accompanying semiannual consolidated financial statements by certified public accountants or auditing firms: None

* Proper use of earnings forecasts, and other special matters

(Note on forward-looking statements, etc.)

Forward-looking statements, such as forecasts of financial results, contained in this document are based on information currently available to the Company and certain assumption that are judged as rational. The Company does not assure the achievement of these forecasts. In addition, actual financial results may differ significantly from forecasts due to various reasons. For assumptions underlying forecasts of financial results and notes regarding the appropriate use of forecasts of financial results, please refer to “1. Overview of Financial Results, Etc., (3) Explanation on Projections such as Forecasts of Consolidated Financial Results” on page 4 of the attached material.

■ Table of Contents for Attached Material

1. Overview of Financial Results, Etc. 2
(1) Overview of Semiannual Financial Results 2
(2) Overview of Semiannual Financial Conditions 3
(3) Explanation on Projections such as Forecasts of Consolidated Financial Results 4
2. Semiannual Consolidated Financial Statements and Important Notes 5
(1) Semiannual Consolidated Balance Sheets 5
(2) Semiannual Consolidated Statements of Income and Consolidated Statements of Comprehensive Income 7
(Semiannual Consolidated Statements of Income) 7
(Semiannual Consolidated Statements of Comprehensive Income) 8
(3) Semiannual consolidated statements of cash flows 9
(4) Notes to Semiannual Consolidated Financial Statements 10
(Notes on segment information) 10
(Notes on any significant changes in the amount of shareholders' equity) 10
(Notes on going concern assumption) 10
(Note on significant subsequent events) 10
3. Other 11
R&D Pipeline 11

1. Overview of Financial Results, Etc.

(1) Overview of Semiannual Financial Results

[1] Financial results for the Six Months Ended September 30, 2026

Net sales amounted to 19,974 million yen (down 6.5% year on year).
Sales of IZCARGO™ for I.V. Infusion , a treatment for mucopolysaccharidosis type II, remained strong. However, due to a decrease in Contract revenue and a decline in revenue for GROWJECT™, the human growth hormone product, net sales decreased by 1,388 million yen compared to the same period of the previous year.

R&D expenses totaled 10,230 million yen (up 2,395 million yen, or 30.6%, year on year) reflecting proactive R&D activities and progress in global clinical development.
As a result, the Company recorded an operating loss of 3,504 million yen (operating profit of 2,429 million yen in the same period of the previous fiscal year), an ordinary loss of 3,798 million yen (ordinary profit of 2,413 million yen in the same period of the previous fiscal year) , and a loss attributable to owners of parent of 3,867 million yen (profit attributable to owners of parent of 1,746 million yen in the same period of the previous fiscal year).

	Previous semiannual consolidated results (cumulative) (April 1, 2025 to September 30, 2025)	Current semiannual consolidated results (cumulative) (April 1, 2026 to September 30, 2026)	Rate of change
	Amount (Million yen)	Amount (Million yen)	%
Net sales	21,362	19,974	(6.5)
Operating profit (loss)	2,429	(3,504)	—
Ordinary profit (loss)	2,413	(3,798)	—
Profit (loss) attributable to owners of parent	1,746	(3,867)	—

[2] Main components of sales

	Previous semiannual consolidated results (cumulative) (April 1, 2025 to September 30, 2025)	Current semiannual consolidated results (cumulative) (April 1, 2026 to September 30, 2026)	Rate of change
	Amount (Million yen)	Amount (Million yen)	%
Human growth hormone product **GROWJECT™**	8,915	7,888	(11.5)
Treatment for mucopolysaccharidosis type II **IZCARGO™ for I.V. Infusion**	3,354	3,634	8.4
Treatment for renal anemia	1,580	1,697	7.4
Epoetin Alfa BS Inj. [JCR]	296	460	55.6
Darbepoetin Alfa BS Inj. [JCR]	1,283	1,236	(3.7)
Regenerative medicine products **TEMCELL™ HS Inj.**	1,582	1,323	(16.4)
Treatment for Fabry disease **Agalsidase Beta BS I.V. Infusion [JCR]**	426	958	125.1
Total	15,858	15,503	(2.2)
Contract revenue	5,015	1,474	(70.6)

[3] The Status of Research and Development (R&D)

[Lysosomal Storage Disorder (LSD) Treatments]

- We are currently focusing on the research and development of over 17 LSD treatments, utilizing our proprietary blood-brain barrier (BBB) penetration technology, J-Brain Cargo®.

- For pabinafusp alfa (JR-141), a BBB-penetrating enzyme replacement therapy for Hunter syndrome, we are progressing with global Phase III clinical trials. These trials are progressing smoothly, and the target number of cases has been achieved. In addition, we held a meeting with the U.S. Food and Drug Administration (FDA) in June 2025 to discuss our strategy for new drug application (NDA), and we have continued discussions with regulatory authorities since then. Regarding global partnering, we entered into an exclusive license agreement with Italfarmaco S.p.A. in October 2026 for the development and commercialization of JR-141 in the U.S., Europe, and Latin America. In countries across the Middle East and North Africa (MENA) region, having entered into a marketing and distribution agreement with Taiba Middle East FZ LLC, and based on the product's marketing authorization in Japan, we received marketing authorization in the United Arab Emirates in July 2026 and conditional marketing authorization in Kuwait in October of the same year.

- For lepunafusp alfa (JR-171), a BBB-penetrating enzyme replacement therapy for mucopolysaccharidosis type I, we have completed a 13-week Phase I/II clinical trial and its extension study in Japan, Brazil, and the U.S. We intend to develop this product through licensing out and are in ongoing negotiations with potential partners.

- For posnafusp alfa (JR-441), a BBB-penetrating enzyme replacement therapy for mucopolysaccharidosis type IIIA, a Phase I/II clinical trial is underway in Germany, and the planned enrollment was completed. We have also enrolled the target number of patients for Phase I trials in Japan, and the trials are progressing smoothly. Additionally, it was granted orphan drug designation by the

European Commission (EC) in January 2022, by the U.S. Food and Drug Administration (FDA) in December 2023, and the Ministry of Health, Labour and Welfare of Japan in December 2024.

- For JR-446, a BBB-penetrating enzyme replacement therapy for mucopolysaccharidosis type IIIB, we entered into a licensing agreement for overseas commercialization and a co-development and commercialization agreement in Japan with MEDIPAL HOLDINGS CORPORATION in September 2023. In December 2024, administration of the investigational drug in a Phase I/II clinical trial began in Japan, and in September 2026, administration of the investigational drug in global Phase I/II clinical trial began. Additionally, it was granted orphan drug designation by the FDA in April 2025, the EC in June 2025, and by the Ministry of Health, Labour and Welfare of Japan in September 2025.

- For JR-471, a BBB-penetrating enzyme replacement therapy candidate for fucosidosis using J-Brain Cargo®, we have granted MEDIPAL HOLDINGS CORPORATION an exclusive license, including sublicensing rights, for the research, development, manufacturing, and commercialization of the product outside Japan, under a licensing agreement signed in October 2022. Clinical research is currently being conducted to collect natural history data of this disease. Furthermore, in August 2025, the two companies have signed an exclusive global licensing deal and a co-development and commercialization partnership in Japan for JR-479, an investigational therapy for GM2 gangliosidosis.

[Human Growth Hormone Products]

- Regarding redalsomatropin alfa (JR-142), a long-acting recombinant human growth hormone preparation, we have completed patient enrollment for the Phase III clinical trial currently underway in Japan for pediatric growth hormone deficiency. Meanwhile, the extension study of the Phase II clinical trial is still ongoing.

- For the marketed product GROWJECT™, we have initiated a Phase III dose-comparison clinical trial in Japan targeting patients with pediatric growth hormone deficiency (JR-401G). This trial aims to close the gap in dosage and administration between Japan and other countries for this condition, with the expectation of further improving final height and quality of life following growth hormone therapy in Japan.

[Duchenne muscular dystrophy treatment]

- In December 2025, the Company acquired an exclusive license from Italfarmaco S.p.A. for the development and commercialization in Japan of givinostat (marketed as Duvyzat® in the US, UK and EU), a treatment drug for Duchenne muscular dystrophy. Based primarily on the results of clinical trials conducted overseas, we plan to submit a marketing authorization application for this drug in Japan by the end of 2026. In September 2026, it was granted orphan drug designation and priority review status by the Ministry of Health, Labour and Welfare of Japan.

[Creation of Platform Technologies]

J-Brain Cargo®

- In addition to expanding the applicability of JCR's proprietary J-Brain Cargo® technology to various modalities, we are focusing on licensing out of this technology. In July 2025, we entered into an option agreement with Acumen Pharmaceuticals, Inc. for the licensing of the J-Brain Cargo® technology for the development of a blood-brain barrier-penetrating Alzheimer's disease treatment, and this company exercised its option in June 2026.

JUST-AAV

- We are focusing on creating new platform technologies beyond J-Brain Cargo®. One of the outcomes of these efforts is the creation of a new gene therapy technology called 'JUST-AAV' using adeno-associated virus (AAV) vectors. This technology not only enables efficient delivery of vectors to specific tissues but also reduces vector accumulation in the liver, which is expected to mitigate side effects. It is currently under development as a new platform technology. In December 2023, we began joint research with Modalis Therapeutics Corporation to develop new gene therapies using this technology. In January 2025, we validated the initial proof of concept, we concluded to proceed to the next phase of their research by entering into a new joint research agreement. In addition, in July 2025, we entered into a license agreement with Alexion, AstraZeneca Rare Diseases to license the JUST-AAV capsids for the development of new genomic medicines.

[Other]

- In December 2025, the Company entered into an agreement with Italfarmaco S.p.A. for strategic collaboration in drugs for rare diseases. This agreement aims to expand both companies' portfolios including exploring joint opportunities across JCR's R&D pipeline and platform technologies.

- We established the Advanced Biopharmaceutical Research Institute at Creative Lab for Innovation in Kobe (CLIK) within the Kobe Biomedical Innovation Cluster (KBIC) to advance biopharmaceutical research and platform technologies. (commenced operations on April 1, 2026)

(2) Overview of Semiannual Financial Conditions

[1] Status of Assets, Liabilities, and Net Assets

As of September 30, 2026, total assets amounted to 113,876 million yen (an increase of 4,640 million yen from March 31, 2026), total liabilities were 72,487 million yen (an increase of 10,610 million yen from March 31, 2026), and total net assets were 41,389 million yen (a decrease of 5,969 million yen from March 31, 2026).

Current assets decreased by 1,408 million yen from March 31, 2026 to 54,667 million yen primarily due to a decrease in cash and deposits, despite increases in accounts receivable - trade, and contract assets, as well as in inventory. Non-current assets increased by 6,049 million yen from March 31, 2026 to 59,209 million yen primarily due to an increase in construction in progress.

Current liabilities increased by 10,945 million yen from March 31, 2026 to 59,080 million yen primarily due to an increase in short term borrowings. Non-current liabilities decreased by 335 million yen from March 31, 2026 to 13,406 million yen, primarily due to a decrease in long-term borrowings.

Net assets decreased by 5,969 million yen from March 31, 2026 to 41,389 million yen primarily due to the recording of a loss attributable to owners of parent and the payment of dividends.
As a result, the equity ratio as of September 30, 2026 was 35.9%, down 7.0 percentage points from March 31, 2026.
In order to achieve sustainable global growth, we need to secure a flexible and stable source of funds. We concluded commitment line agreements with our financial institutions for a total of 49,500 million yen for the purpose of securing operating funds as a backup line.
Of this amount, 26,500 million yen has been concluded to finance the construction of a new plant for drug product filling and finishing. The construction of this new plant has been adopted by the Ministry of Economy, Trade and Industry (METI) under the project of Establishing Biopharmaceutical Manufacturing Sites to Strengthen Vaccine Production, and the subsidy from this project will be used to construct the new plant. The purpose of the commitment line agreement is to provide the necessary funds until we receive the subsidy.

[2] Status of Cash Flows

Cash and cash equivalents as of September 30, 2026 decreased by 3,571 million yen from March 31, 2026 to 10,435 million yen.
The details of the cash flows and their primary causes are as follows:

(Cash Flow from Operating Activities)

Operating activities resulted in a cash outflow of 3,804 million yen. This was primarily due to the recognition of a loss before income taxes of 3,808 million yen.

(Cash Flow from Investing Activities)

Investing activities resulted in a cash outflow of 8,267 million yen. This was primarily driven by the purchase of property, plant and equipment of 7,799 million yen.

(Cash Flow from Financing Activities)

Financing activities resulted in a cash inflow of 8,524 million yen. This was primarily due to a dividend payment of 1,220 million yen, and a net increase in short-term borrowings of 10,514 million yen.

(3) Explanation on Projections such as Forecasts of Consolidated Financial Results

Consolidated financial results for the six months ended September 30, 2026 showed a year-on-year decline in both net sales and profits. There are no changes to the forecasts for the fiscal year ending March 31, 2027 announced on May 13, 2026.

2. Semiannual Consolidated Financial Statements and Important Notes

(1) Semiannual Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2026	As of September 30, 2026
Assets		
Current assets		
Cash and deposits	14,007	10,435
Accounts receivable - trade, and contract assets	14,163	15,042
Merchandise and finished goods	2,117	4,340
Work in process	6,908	5,970
Raw materials and supplies	15,016	14,674
Other	3,864	4,205
Allowance for doubtful accounts	(1)	(1)
Total current assets	56,076	54,667
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	6,598	7,768
Land	11,029	11,029
Construction in progress	19,411	24,753
Other, net	2,204	2,548
Total property, plant and equipment	39,244	46,099
Intangible assets		
Patent right	1,604	1,466
Other	992	839
Total intangible assets	2,596	2,305
Investments and other assets		
Investment securities	7,833	6,577
Other	3,489	4,231
Allowance for doubtful accounts	(4)	(4)
Total investments and other assets	11,318	10,804
Total non-current assets	53,160	59,209
Total assets	109,236	113,876
Liabilities		
Current liabilities		
Accounts payable - trade	523	1,092
Short-term borrowings	41,692	51,806
Provision for bonuses	1,136	1,466
Provision for bonuses for directors (and other officers)	125	65
Other	4,658	4,650
Total current liabilities	48,135	59,080
Non-current liabilities		
Long-term borrowings	12,200	11,850
Provision for employee stock ownership plan	129	116
Retirement benefit liability	914	962
Special suspense account for tax purpose reduction entry	245	245
Other	252	232
Total non-current liabilities	13,741	13,406
Total liabilities	61,877	72,487

(Millions of yen)

	As of March 31, 2026	As of September 30, 2026
Net assets		
Shareholders' equity		
Share capital	9,061	9,061
Capital surplus	10,378	10,347
Retained earnings	31,226	26,136
Treasury shares	(4,969)	(4,799)
Total shareholders' equity	45,697	40,745
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	438	(593)
Deferred gains or losses on hedges	(2)	3
Foreign currency translation adjustment	533	590
Remeasurements of defined benefit plans	200	175
Total accumulated other comprehensive income	1,170	175
Share acquisition rights	72	46
Non-controlling interests	417	420
Total net assets	47,359	41,389
Total liabilities and net assets	109,236	113,876

(2) Semiannual Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

(Semiannual Consolidated Statements of Income)

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Net sales	21,362	19,974
Cost of sales	4,273	5,752
Gross profit	17,089	14,221
Selling, general and administrative expenses	14,659	17,726
Operating profit (loss)	2,429	(3,504)
Non-operating income		
Interest income	38	30
Dividend income	21	16
Gain on sale of investment securities	41	—
Foreign exchange gains	158	—
Compensation income	47	159
Other	45	26
Total non-operating income	353	232
Non-operating expenses		
Share of loss of entities accounted for using equity method	91	94
Interest expenses	157	337
Foreign exchange losses	—	42
Other	121	51
Total non-operating expenses	370	526
Ordinary profit (loss)	2,413	(3,798)
Extraordinary income		
Gain on sale of investment securities	209	—
Total extraordinary income	209	—
Extraordinary losses		
Loss on disposal of non-current assets	31	10
Total extraordinary losses	31	10
Profit (loss) before income taxes	2,591	(3,808)
Income taxes - current	252	33
Income taxes - deferred	596	35
Total income taxes	849	68
Profit (loss)	1,742	(3,877)
Loss attributable to non-controlling interests	(3)	(9)
Profit (loss) attributable to owners of parent	1,746	(3,867)

(Semiannual Consolidated Statements of Comprehensive Income)

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Profit (loss)	1,742	(3,877)
Other comprehensive income		
Valuation difference on available-for-sale securities	578	(1,032)
Deferred gains or losses on hedges	(1)	5
Foreign currency translation adjustment	(50)	69
Remeasurements of defined benefit plans, net of tax	(6)	(24)
Total other comprehensive income	520	(982)
Comprehensive income	2,263	(4,859)
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	2,294	(4,862)
Comprehensive income attributable to non-controlling interests	(30)	3

(3) Semiannual consolidated statements of cash flows

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from operating activities		
Profit (loss) before income taxes	2,591	(3,808)
Depreciation	1,459	1,081
Loss (gain) on sale of investment securities	(251)	4
Increase (decrease) in provision for bonuses	278	330
Share-based payment expenses	27	36
Interest and dividend income	(59)	(46)
Interest expenses	157	337
Foreign exchange losses (gains)	(81)	72
Decrease (increase) in trade receivables	(1,409)	(878)
Decrease (increase) in accounts receivable - other	512	(93)
Decrease (increase) in inventories	(1,706)	(943)
Increase (decrease) in trade payables	462	568
Increase (decrease) in accounts payable - other	(318)	778
Increase (decrease) in accrued consumption taxes	453	(401)
Decrease (increase) in prepaid expenses	(90)	(526)
Other, net	(500)	225
Subtotal	1,526	(3,263)
Interest and dividends received	59	46
Interest paid	(152)	(345)
Income taxes refund (paid)	783	(242)
Net cash provided by (used in) operating activities	2,216	(3,804)
Cash flows from investing activities		
Purchase of property, plant and equipment	(792)	(7,799)
Proceeds from sale and redemption of investment securities	293	17
Purchase of shares of subsidiaries and associates	—	(350)
Other, net	(88)	(134)
Net cash provided by (used in) investing activities	(587)	(8,267)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	4,200	10,514
Proceeds from long-term borrowings	—	200
Repayments of long-term borrowings	(2,200)	(950)
Net decrease (increase) in treasury shares	5	2
Dividends paid	(1,220)	(1,220)
Other, net	(27)	(21)
Net cash provided by (used in) financing activities	758	8,524
Effect of exchange rate change on cash and cash equivalents	38	(25)
Net increase (decrease) in cash and cash equivalents	2,425	(3,571)
Cash and cash equivalents at beginning of period	13,196	14,007
Cash and cash equivalents at end of period	15,621	10,435

(4) Notes to Semiannual Consolidated Financial Statements

(Notes on segment information)
Segment information is not disclosed since the Group has only one segment, Pharmaceuticals.

(Notes on any significant changes in the amount of shareholders' equity)
Not applicable.

(Notes on going concern assumption)
Not applicable.

(Note on significant subsequent events)
(Execution of a Significant Agreement)
The Company has entered into an exclusive license agreement with Italfarmaco S.p.A. regarding the development and commercialization in the U.S., Europe, and Latin America of JR-141 (INN: pabinafusp alfa; Japanese brand name IZCARGO™), a blood-brain barrier-penetrating enzyme replacement therapy for Hunter syndrome using J-Brain Cargo® technology, for which the Company has already obtained marketing approval in Japan.

(1) Purpose or Reason for the Agreement
To promote the development and commercialization of JR-141, a blood-brain barrier-penetrating enzyme replacement therapy for Hunter syndrome, in the U.S., Europe, and Latin America

(2) Name of the Counterparty
Italfarmaco S.p.A.

(3) Date of the Agreement
October 2, 2026

(4) Description of the Agreement
An exclusive license agreement for the development and commercialization in the U.S., Europe, and Latin America of JR-141 a blood-brain barrier-penetrating enzyme replacement therapy for Hunter syndrome.

(5) Significant Impact of the Agreement on Business Operations, etc.
Upon execution of the Agreement, the Company will receive an upfront payment from Italfarmaco S.p.A. In addition, the Company is entitled to receive milestone payments based on development progress in each territory. Following commercialization, the Company will be entitled to receive royalty payments based on net sales, milestone payments tied to the achievement of specified sales targets, as well as revenues associated with product supply.

3. Other

R&D Pipeline

Code	Status	Potential Indication / Remarks
JR-141 BBB-Penetrating Iduronate-2-sulfatase (rDNA origin)	Global: Phase III	Mucopolysaccharidosis II (Hunter syndrome)
		ERT J-Brain Cargo®
JR-142 Long-acting Growth hormone (rDNA origin)	Japan: Phase III	Pediatric growth hormone deficiency
		J-MIG System®
JR-401G Growth hormone (rDNA origin)	Japan: Phase III	Pediatric growth hormone deficiency
		Development of GROWJECT™ for dosing regimen that allows dose adjustment
JR-171 BBB-Penetrating α-L-Iduronidase (rDNA origin)	Global: Phase I/II	Mucopolysaccharidosis I (Hurler syndrome, etc.)
		ERT J-Brain Cargo® J-MIG System®
JR-441 BBB-Penetrating heparan N-sulfatase (rDNA origin)	Germany: Phase I/II Japan: Phase I	Mucopolysaccharidosis IIIA (Sanfilippo syndrome type A)
		ERT J-Brain Cargo®
JR-446 BBB-Penetrating α-N-acetylglucosaminidase (rDNA origin)	Japan: Phase I/II Global: Phase I/II	Mucopolysaccharidosis IIIB (Sanfilippo syndrome type B)
		ERT J-Brain Cargo®
givinostat	Progressing preparations for a marketing authorization application in Japan	Duchenne muscular dystrophy
		Licensed from Italfarmaco S.p.A.
JR-471 BBB-penetrating α-L-fucosidase (rDNA origin)	Preclinical	Fucosidosis
		ERT J-Brain Cargo®
JR-479 BBB-penetrating β-Hexosaminidase A (rDNA origin)	Preclinical	GM2 gangliosidosis (Tay-Sachs disease, Sandhoff disease)
		ERT J-Brain Cargo®

(Note) ERT= Enzyme Replacement Therapy